KALVISTA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: The election of two Class II directors to hold office until the earliest of our 2026 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: PATRICK TREANOR

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Treanor”): 15,931,760 for, 6,722,475 against, per its Form 8-K filed September 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 2,573,548 for, 1,256,043 against.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: The election of two Class II directors to hold office until the earliest of our 2026 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: EDWARD W. UNKART

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Edward W. Unkart”): 15,154,122 for, 7,499,378 against, per its Form 8-K filed September 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 2,394,420 for, 1,435,171 against.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Approval of a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted pursuant to recent amendments to the Delaware General Corporation Law.

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“4. Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law”): 20,203,486 for, 2,450,421 against, per its Form 8-K filed September 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 3,687,197 for, 142,394 against.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers”): 20,001,348 for, 2,652,134 against, per its Form 8-K filed September 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 43 managers: 3,424,280 for, 405,311 against. Showing the 25 largest; see all in the interactive database.

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: The ratification of the selection, by the audit committee of our Board, of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending April 30, 2024.

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024”): 30,837,741 for, 1,624 against, per its Form 8-K filed September 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 3,829,591 for.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.